バイオ医薬品添加剤市場：製品、供給元、製剤タイプ、エンドユーザー別-2025-2030年の世界予測

バイオ医薬品添加剤市場の2024年の市場規模は36億1,000万米ドルで、2025年にはCAGR 9.69%で39億6,000万米ドルに成長し、2030年には63億米ドルに達すると予測されています。

バイオ医薬品の賦形剤は、医薬品有効成分を送達する手段だけでなく、安定性、バイオアベイラビリティ、患者のコンプライアンスを高めるソリューションも提供し、最新の治療法の製剤化において重要なコンポーネントとして浮上してきました。時間の経過とともに、賦形剤は単なる不活性な担体から、製品の性能に積極的に寄与するものへと進化してきました。この変化は、科学と工学の両分野における進歩によってもたらされ、厳しい品質基準と規制要件を満たす、より洗練された材料へと変化してきました。現在の市場環境は、強力な研究イニシアティブとダイナミックな技術開発が交差していることを反映しており、製造プロセスの改善と革新的な成分設計が治療用途を再定義しています。さらに、化学技術者、バイオ医薬品科学者、製造技術者の継続的な連携が、この分野における技術革新の次の波に拍車をかけています。その結果、利害関係者は現在、有効性と安全性のバランスをとるためのより優れた能力を備え、複雑な治療法や患者のニーズに対応する高度に専門化された医薬品への道を開いています。本書では、市場力学、セグメント特有のニュアンス、そして競合環境が急速に拡大する中で業界プレイヤーを導く戦略的必須事項を包括的に検討します。

バイオ医薬品添加剤の情勢における変革的変化

市場力学がイノベーション、効率性、規制遵守にかつてない影響を及ぼす中、バイオ医薬品添加剤の状況は変革期を迎えています。急速な技術の進歩と生産手法の強化により、より純粋で高機能な化合物の創出が促進され、厳しい品質基準を確実に満たしながら製品性能を向上させています。従来の化学由来成分から、高度なポリマー科学と強化された生物活性特性を組み合わせた新規配合への移行が顕著になっています。また、持続可能な調達やより環境に優しい生産方法へのシフトも、企業が経済成長と環境責任の両立に努める中で、焦点となっています。このような進化は、世界な研究機関と業界のパイオニアとの強固な研究開発投資と戦略的協力関係によって後押しされており、これらは共に、賦形剤の機能性を最適化するための学際的な洞察を促進しています。さらに、個別化医療と高精度ドラッグデリバリーへの注目の高まりは、特定の治療様式や患者層に対応する製剤の再設計につながっています。このような革新的な動向は、絶え間ないイノベーションと適応戦略を特徴とする市場開拓の舞台を整え、賦形剤の医薬品開発への貢献のあり方を根本的に変えています。その結果、業界は長期的な成功に不可欠な差別化、コスト効率、治療成績向上の機会を見出すことになります。

市場セグメンテーションによる詳細な市場分析

詳細なセグメンテーション分析により、包括的かつダイナミックなバイオ医薬品賦形剤市場への多面的アプローチが明らかになりました。製品ベースのセグメンテーションのプリズムを通して観察すると、市場は結合剤、コーティング剤、希釈剤、崩壊剤、滑沢剤および滑沢剤、ポリオール、防腐剤、可溶化剤、界面活性剤/乳化剤、懸濁剤および粘度剤などの専門分野に分類されます。結合剤では、セルロース系結合剤、ヒドロキシプロピルメチルセルロース（HPMC）、ポビドン（ポリビニルピロリドンまたはPVP）、澱粉や変性澱粉などの細分化により、さらなる特異性が達成されます。同様に、コーティングは放出制御、腸溶、フィルム、シール、糖衣など様々なタイプが研究されており、希釈剤にはリン酸カルシウム、乳糖、微結晶セルロースなどが含まれます。ポリオールの領域では、マンニトールとソルビトールに焦点が当てられ、可溶化剤と界面活性剤／乳化剤はさらにエステル、ポリソルベート、トリグリセリドに分けられます。さらに、供給源に基づくセグメンテーションにより、天然賦形剤と合成賦形剤が区別されます。さらに、製剤タイプのセグメンテーションは、筋肉内、静脈内、皮下に分類される注射製剤、カプセル、粉末、錠剤を含む経口製剤、クリーム、ゲル、軟膏、ローションに分類される局所製剤に及ぶ。最後に、エンドユーザーのセグメンテーションでは、バイオ製薬会社、製薬会社、受託製造会社、研究機関を取り上げ、これらすべてのセグメンテーションを総合して、市場力学の全領域にわたる詳細な理解を提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の蔓延により、世界中で高度な医薬品製剤が求められるようになっている
    • バイオ医薬品添加剤におけるFDA承認と調査活動の増加
    • 薬剤の安定性と有効性を高める多機能賦形剤への関心が高まっている
  • 抑制要因
    • 開発コストが高く、偽造品や粗悪品の添加剤が流通している
  • 機会
    • 高分子医薬品を支える革新的な添加剤の研究開発の急増
    • 添加剤のサプライチェーンと流通を強化するためのパートナーシップとコラボレーション
  • 課題
    • バイオ医薬品業界における添加剤の規制遵守の複雑さ
• 市場セグメンテーション分析
  • 製品：バイオ医薬品製剤の安定性と機能性を高めるポリオールの多様な役割
  • 製剤タイプ：内容物の安定性を確保するために経口製剤に賦形剤を採用するケースが増加している
  • 出典：生体適合性と再生可能性を理由に天然添加剤への関心が高まっている
  • エンドユーザー：革新的な医薬品製剤のためのバイオ医薬品および製薬会社における賦形剤の利用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 バイオ医薬品添加剤市場：製品別

• バインダー
  • セルロースバインダー
  • ヒドロキシプロピルメチルセルロース（HPMC）
  • ポビドン（ポリビニルピロリドンまたはPVP）
  • デンプンおよび加工デンプン
• コーティング
  • 制御放出コーティング
  • 腸溶コーティング
  • フィルムコーティング
  • シールコーティング
  • 砂糖コーティング
• 希釈剤
  • リン酸カルシウム
  • 乳糖
  • 微結晶セルロース
• 崩壊剤
• 潤滑剤と滑剤
• ポリオール
  • マンニトール
  • ソルビトール
• 防腐剤
• 可溶化剤および界面活性剤/乳化剤
  • エステル
  • ポリソルベート
  • トリグリセリド
• 懸濁剤および増粘剤

第7章 バイオ医薬品添加剤市場：ソース別

• 天然賦形剤
• 合成賦形剤

第8章 バイオ医薬品添加剤市場処方タイプ別

• 注射剤
  • 筋肉内
  • 静脈内
  • 皮下
• 経口製剤
  • カプセル
  • 粉末
  • タブレット
• 局所製剤
  • クリーム
  • ジェルと軟膏
  • ローション

第9章 バイオ医薬品添加剤市場：エンドユーザー別

• バイオ医薬品および製薬会社
• 契約製造業者
• 調査機関

第10章 南北アメリカのバイオ医薬品添加剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のバイオ医薬品添加剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのバイオ医薬品添加剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ABITEC Corporation
• Actylis
• Asahi Kasei Corporation
• Ashland Inc.
• Avantor, Inc.
• BASF SE
• Clariant International Ltd.
• Colorcon Ltd.
• Croda International PLC
• DFE Pharma GmbH & Co KG
• Eastman Chemical Company
• Evonik Industries AG
• Fuji Chemical Industries Co., Ltd.
• IMCD N.V.
• Innophos Holdings, Inc.
• International Flavors & Fragrances Inc.
• JRS PHARMA GmbH+Co. KG
• Kerry Group PLC
• Meggle Group GmbH
• Merck KGaA
• Mitsubishi Chemical Group Corporation
• NOF Corporation
• Novo Nordisk A/S
• Pfanstiehl, Inc.
• Roquette Freres S.A.
• Shin-Etsu Chemical Co., Ltd.
• Sigachi Industries Limited
• Spectrum Laboratory Products, Inc.
• SPI Pharma, Inc. By Associated British Foods
• The Archer-Daniels-Midland Company
• The Dow Chemical Company
• The Lubrizol Corporation
• Wacker Chemie AG

LIST OF FIGURES

• FIGURE 1. BIOPHARMACEUTICAL EXCIPIENTS MARKET MULTI-CURRENCY
• FIGURE 2. BIOPHARMACEUTICAL EXCIPIENTS MARKET MULTI-LANGUAGE
• FIGURE 3. BIOPHARMACEUTICAL EXCIPIENTS MARKET RESEARCH PROCESS
• FIGURE 4. BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. BIOPHARMACEUTICAL EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOPHARMACEUTICAL EXCIPIENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOPHARMACEUTICAL EXCIPIENTS MARKET DYNAMICS
• TABLE 7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CELLULOSIC BINDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE (HPMC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POVIDONE (POLYVINYLPYRROLIDONE OR PVP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STARCH & MODIFIED STARCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CONTROLLED RELEASE COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ENTERIC COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FILM COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SEAL COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUGAR COATINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CALCIUM PHOSPHATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LACTOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DISINTEGRANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LUBRICANTS & GLIDANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRESERVATIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ESTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYSORBATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TRIGLYCERIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUSPENDING & VISCOSITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY NATURAL EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SYNTHETIC EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY GELS & OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BIOPHARMACEUTICAL & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY CONTRACT MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 67. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 68. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 69. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 71. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 72. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 73. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. AMERICAS BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 78. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 79. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 80. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 81. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 82. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 84. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 85. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 86. ARGENTINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 89. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 90. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 91. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 92. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 93. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 94. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 95. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 96. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 97. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 98. BRAZIL BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 101. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 102. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 103. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 104. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 105. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 106. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 107. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 108. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 109. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 110. CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 113. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 114. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 115. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 116. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 117. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 118. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 119. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 120. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 121. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 122. MEXICO BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 125. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 126. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 127. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 128. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 129. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 130. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 131. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 132. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 133. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 134. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. UNITED STATES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 136. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 138. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 140. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 142. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 144. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 146. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. ASIA-PACIFIC BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 149. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 151. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 152. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 153. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 154. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 155. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 156. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 157. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 158. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 159. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 160. AUSTRALIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 163. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 164. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 165. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 166. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 167. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 168. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 169. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 170. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 171. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 172. CHINA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 175. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 176. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 177. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 178. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 179. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 180. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 181. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 182. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 183. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 184. INDIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 187. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 188. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 189. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 190. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 191. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 192. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 193. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 194. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 195. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 196. INDONESIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 199. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 200. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 201. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 202. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 203. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 204. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 205. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 206. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 207. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 208. JAPAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 209. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 211. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 212. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 213. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 214. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 215. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 216. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 217. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 218. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 219. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 220. MALAYSIA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 223. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 224. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 225. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 226. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 227. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 228. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 229. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 230. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 231. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 232. PHILIPPINES BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 234. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 235. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 236. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 237. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 238. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 239. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 240. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 241. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 242. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 243. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 244. SINGAPORE BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH KOREA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 258. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 259. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 260. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 261. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 262. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 263. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 264. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 265. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 266. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 267. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 268. TAIWAN BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 269. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 270. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 271. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 272. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 273. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 274. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 275. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 276. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 277. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 278. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 279. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 280. THAILAND BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 281. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 282. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 283. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 284. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 285. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 286. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 287. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 288. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 289. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 290. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 291. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 292. VIETNAM BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY DILUENTS, 2018-2030 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY POLYOLS, 2018-2030 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOLUBILIZERS & SURFACTANTS/EMULSIFIERS, 2018-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 306. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 307. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY BINDERS, 2018-2030 (USD MILLION)
• TABLE 308. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY COATINGS, 2018-2030 (USD MILLION)
• TABLE 309. DENMARK BIOPHARMACEUTICAL EXCIPIENTS MARKET SIZE, BY D

The Biopharmaceutical Excipients Market was valued at USD 3.61 billion in 2024 and is projected to grow to USD 3.96 billion in 2025, with a CAGR of 9.69%, reaching USD 6.30 billion by 2030.

Biopharmaceutical excipients have emerged as critical components in the formulation of modern therapies, offering not only the means to deliver active pharmaceutical ingredients but also solutions that enhance stability, bioavailability, and patient compliance. Over time, excipients have evolved from mere inert carriers to active contributors to product performance. This transformation has been driven by advancements in both science and engineering, leading to more sophisticated materials that meet stringent quality standards and regulatory requirements. The current market landscape reflects an intersection of robust research initiatives and dynamic technological developments, where improved manufacturing processes and innovative ingredient design are redefining therapeutic applications. Moreover, continuous collaboration between chemical engineers, biopharmaceutical scientists, and production technologists is spurring the next wave of innovations in this field. As a result, stakeholders are now better equipped to balance efficacy with safety, paving the way for highly specialized pharmaceutical products that address complex therapies and patient needs. This evolving narrative sets the stage for a comprehensive exploration of market dynamics, segment-specific nuances, and strategic imperatives that guide industry players in a competitive and rapidly expanding environment.

Transformative Shifts in the Landscape of Biopharmaceutical Excipients

The landscape of biopharmaceutical excipients is undergoing transformative shifts as market dynamics influence innovation, efficiency, and regulatory compliance in unprecedented ways. Rapid technological advancements and enhanced production methodologies are fostering the creation of more pure and high-functionality compounds, driving product performance while ensuring stringent quality standards are met. There has been a noticeable transition from traditional, chemically derived components to novel formulations that combine advanced polymer science with enhanced bioactive characteristics. Shifts towards sustainable sourcing and greener production methods have also become focal points, as companies strive to balance economic growth with environmental responsibility. This evolution is bolstered by robust R&D investments and strategic collaborations across global research institutes and industry pioneers, which together promote cross-disciplinary insights into optimizing excipient functionality. Furthermore, an increased focus on personalized medicine and precision drug delivery has led to redesigned formulations that cater to specific therapeutic modalities and patient demographics. These transformative trends are setting the stage for a market characterized by continuous innovation and adaptive strategies, fundamentally reshaping how excipients contribute to pharmaceutical development. Consequently, the industry sees opportunities for differentiation, cost efficiency, and enhanced therapeutic outcomes that are instrumental for long-term success.

Key Segmentation Insights for a Nuanced Market Analysis

An in-depth segmentation analysis reveals a multifaceted approach to the biopharmaceutical excipients market that is both comprehensive and dynamic. When observed through the prism of product-based segmentation, the market is carved into specialized areas such as binders, coatings, diluents, disintegrants, lubricants and glidants, polyols, preservatives, solubilizers and surfactants/emulsifiers, along with suspending and viscosity agents. Within binders, further specificity is achieved through subdivisions like cellulosic binders, hydroxypropyl methylcellulose (HPMC), povidone (polyvinylpyrrolidone or PVP), as well as starch and modified starches. Similarly, coatings are studied across various types including controlled release, enteric, film, seal, and sugar coatings, while diluents encompass calcium phosphates, lactose, and microcrystalline cellulose. In the realm of polyols, the focus is on mannitol and sorbitol, and solubilizers and surfactants/emulsifiers are further dissected into esters, polysorbates, and triglycerides. Additionally, segmentation based on source differentiates natural from synthetic excipients. Further, formulation type segmentation spans injectable formulations-classified into intramuscular, intravenous, and subcutaneous-oral formulations including capsules, powders, and tablets, and topical formulations divided into creams, gels and ointments, and lotions. Last, end user segmentation addresses biopharmaceutical and pharmaceutical companies, contract manufacturers, and research institutes, all of which collectively provide a granular understanding across the full spectrum of market dynamics.

Based on Product, market is studied across Binders, Coatings, Diluents, Disintegrants, Lubricants & Glidants, Polyols, Preservatives, Solubilizers & Surfactants/Emulsifiers, and Suspending & Viscosity Agents. The Binders is further studied across Cellulosic Binders, Hydroxypropyl Methylcellulose (HPMC), Povidone (Polyvinylpyrrolidone or PVP), and Starch & Modified Starches. The Coatings is further studied across Controlled Release Coatings, Enteric Coatings, Film Coatings, Seal Coatings, and Sugar Coatings. The Diluents is further studied across Calcium Phosphates, Lactose, and Microcrystalline Cellulose. The Polyols is further studied across Mannitol and Sorbitol. The Solubilizers & Surfactants/Emulsifiers is further studied across Esters, Polysorbates, and Triglycerides.

Based on Source, market is studied across Natural Excipients and Synthetic Excipients.

Based on Formulation Type, market is studied across Injectable Formulations, Oral Formulations, and Topical Formulations. The Injectable Formulations is further studied across Intramuscular, Intravenous, and Subcutaneous. The Oral Formulations is further studied across Capsules, Powders, and Tablets. The Topical Formulations is further studied across Creams, Gels & Ointments, and Lotions.

Based on End User, market is studied across Biopharmaceutical & Pharmaceutical Companies, Contract Manufacturers, and Research Institutes.

Key Regional Insights Shaping Global Market Dynamics

A comprehensive regional analysis uncovers distinct trends and growth drivers tailored to diverse geographical markets. In the Americas, robust healthcare infrastructure and progressive regulatory frameworks serve as catalysts for innovation, enabling swift adoption of new technologies that improve therapeutic efficacy. Latin America, as a subset of this region, offers significant opportunities driven by growing investments in biopharmaceutical manufacturing and favorable government policies. Across the broad expanse of Europe, the Middle East, and Africa, there exists a blend of mature markets and emerging economies. In Europe, stringent quality standards and pioneering research activities facilitate the continuous evolution of excipient applications, while markets within the Middle East and Africa are beginning to harness the benefits of modern pharmaceutical practices. Meanwhile, the Asia-Pacific region is distinguished by rapid industrial expansion, rising investments in healthcare, and an increasing demand for cost-efficient yet high-quality pharmaceutical components. This geographical diversity not only underscores the importance of localized insights but also reflects the varied pace of technological adoption and market maturation across continents, each contributing uniquely to the accelerated growth of biopharmaceutical excipients on the global stage.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Fueling Market Innovation

The competitive arena in biopharmaceutical excipients is marked by the presence of several leading companies that consistently push the boundaries of innovation and quality. Industry leaders such as ABITEC Corporation, Actylis, Asahi Kasei Corporation, and Ashland Inc. are continually refining production techniques to enhance product efficacy and regulatory compliance. Company profiles extend to organizations like Avantor, Inc., BASF SE, Clariant International Ltd., and Colorcon Ltd., which leverage deep technical expertise and comprehensive R&D investments to drive market expansion. Further, Croda International PLC, DFE Pharma GmbH & Co KG, and Eastman Chemical Company have all demonstrated a strong commitment to sustainability and process optimization. In addition, the contributions of Evonik Industries AG, Fuji Chemical Industries Co., Ltd., IMCD N.V., Innophos Holdings, Inc., and International Flavors & Fragrances Inc. underscore a dedicated pursuit of novel excipient applications. Other significant players include JRS PHARMA GmbH + Co. KG, Kerry Group PLC, Meggle Group GmbH, Merck KGaA, Mitsubishi Chemical Group Corporation, NOF Corporation, Novo Nordisk A/S, Pfanstiehl, Inc., and Roquette Freres S.A., complemented by the innovative strides made by Shin-Etsu Chemical Co., Ltd., Sigachi Industries Limited, Spectrum Laboratory Products, Inc., SPI Pharma, Inc., By Associated British Foods, The Archer-Daniels-Midland Company, The Dow Chemical Company, The Lubrizol Corporation, and Wacker Chemie AG. Their strategic investments and domain expertise are instrumental in setting market benchmarks and driving cohesive progress.

The report delves into recent significant developments in the Biopharmaceutical Excipients Market, highlighting leading vendors and their innovative profiles. These include ABITEC Corporation, Actylis, Asahi Kasei Corporation, Ashland Inc., Avantor, Inc., BASF SE, Clariant International Ltd., Colorcon Ltd., Croda International PLC, DFE Pharma GmbH & Co KG, Eastman Chemical Company, Evonik Industries AG, Fuji Chemical Industries Co., Ltd., IMCD N.V., Innophos Holdings, Inc., International Flavors & Fragrances Inc., JRS PHARMA GmbH + Co. KG, Kerry Group PLC, Meggle Group GmbH, Merck KGaA, Mitsubishi Chemical Group Corporation, NOF Corporation, Novo Nordisk A/S, Pfanstiehl, Inc., Roquette Freres S.A., Shin-Etsu Chemical Co., Ltd., Sigachi Industries Limited, Spectrum Laboratory Products, Inc., SPI Pharma, Inc. By Associated British Foods, The Archer-Daniels-Midland Company, The Dow Chemical Company, The Lubrizol Corporation, and Wacker Chemie AG. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to embrace a proactive approach by investing in research and development aimed at increasing both the performance and safety profiles of biopharmaceutical excipients. Strategic collaborations with academic institutions and technology innovators can facilitate pilot projects that evaluate novel material properties and process improvements. It is recommended that companies undertake robust risk assessments to align with evolving regulatory frameworks and consumer expectations, while simultaneously exploring sustainable sourcing practices to reduce environmental impact. By incorporating advanced analytics in trend forecasting and supply chain optimization, organizations can maintain a competitive edge in an increasingly dynamic market. Enhancing interdepartmental collaboration and leveraging digital transformation will further streamline decision-making processes, ultimately driving significant improvements in operational efficiency and product innovation.

Conclusion: Navigating a Future of Unprecedented Growth

The biopharmaceutical excipients market is at a pivotal juncture where innovation meets traditional expertise. Continuous advancements in formulation science, process optimization, and sustainable practices signal a future rich with growth potential. This dynamic environment calls for strategic foresight and adaptable business models that can meet the demands of a rapidly evolving therapeutic landscape. With an emphasis on quality, efficiency, and actionable insights derived from thorough segmentation and regional analyses, industry stakeholders are well-positioned to harness emerging opportunities. The journey forward will depend upon a commitment to innovation and a clear understanding of the intricate interplay between technology, market demands, and regulatory considerations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases necessitating advanced drug formulations globally
    • 5.1.1.2. Rising FDA approvals and research activities in biopharmaceutical excipients
    • 5.1.1.3. Growing preference for multifunctional excipients offering enhanced drug stability and efficacy
  • 5.1.2. Restraints
    • 5.1.2.1. High development costs and availability of counterfeit and substandard excipients
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in research and development for innovative excipients to support large molecule drugs
    • 5.1.3.2. Partnerships & collaborations to enhance excipient supply chains and distribution
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities of regulatory compliance for excipients in the biopharmaceutical industry
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Versatile role of polyols in enhancing stability and functionality of biopharmaceutical formulations
  • 5.2.2. Formulation Type: Increasing adoption of excipients in oral formulations to ensure content stability
  • 5.2.3. Source: Growing preference for natural excipients for their biocompatibility and renewable nature
  • 5.2.4. End User: Rising utilization excipients across biopharmaceutical & pharmaceutical companies for innovative drug formulations
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biopharmaceutical Excipients Market, by Product

• 6.1. Introduction
• 6.2. Binders
  • 6.2.1. Cellulosic Binders
  • 6.2.2. Hydroxypropyl Methylcellulose (HPMC)
  • 6.2.3. Povidone (Polyvinylpyrrolidone or PVP)
  • 6.2.4. Starch & Modified Starches
• 6.3. Coatings
  • 6.3.1. Controlled Release Coatings
  • 6.3.2. Enteric Coatings
  • 6.3.3. Film Coatings
  • 6.3.4. Seal Coatings
  • 6.3.5. Sugar Coatings
• 6.4. Diluents
  • 6.4.1. Calcium Phosphates
  • 6.4.2. Lactose
  • 6.4.3. Microcrystalline Cellulose
• 6.5. Disintegrants
• 6.6. Lubricants & Glidants
• 6.7. Polyols
  • 6.7.1. Mannitol
  • 6.7.2. Sorbitol
• 6.8. Preservatives
• 6.9. Solubilizers & Surfactants/Emulsifiers
  • 6.9.1. Esters
  • 6.9.2. Polysorbates
  • 6.9.3. Triglycerides
• 6.10. Suspending & Viscosity Agents

7. Biopharmaceutical Excipients Market, by Source

• 7.1. Introduction
• 7.2. Natural Excipients
• 7.3. Synthetic Excipients

8. Biopharmaceutical Excipients Market, by Formulation Type

• 8.1. Introduction
• 8.2. Injectable Formulations
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral Formulations
  • 8.3.1. Capsules
  • 8.3.2. Powders
  • 8.3.3. Tablets
• 8.4. Topical Formulations
  • 8.4.1. Creams
  • 8.4.2. Gels & Ointments
  • 8.4.3. Lotions

9. Biopharmaceutical Excipients Market, by End User

• 9.1. Introduction
• 9.2. Biopharmaceutical & Pharmaceutical Companies
• 9.3. Contract Manufacturers
• 9.4. Research Institutes

10. Americas Biopharmaceutical Excipients Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biopharmaceutical Excipients Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biopharmaceutical Excipients Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Nucleus Biologics secures EXCiPACT certification to enhancing quality and compliance in biopharmaceutical excipients
  • 13.3.2. Nagase Viita to launch injectable-grade SUCROSE SG in 2025
  • 13.3.3. Ashland launch innovative excipient solutions to enhance pharmaceutical formulations at CPHI Milan and AAPS PharmSci 360
  • 13.3.4. VION Biosciences expands lipid capabilities with acquisition of Echelon Biosciences
  • 13.3.5. Roquette to acquire IFF Pharma Solutions to strengthen its position in the biopharmaceutical excipients market
  • 13.3.6. Azelis expands biopharmaceutical portfolio through partnership with Anhui Sunhere
  • 13.3.7. Barentz enters U.S. distribution agreement for Ashland's vialose parenteral excipient
  • 13.3.8. BASF and IFF collaborate to enhance formulation efficiency with ZoomLab integration
  • 13.3.9. Roquette launch advanced excipient grades for enhanced moisture protection at CPHI Barcelona
  • 13.3.10. Clariant launch innovative high-purity excipients to enhance API stability and solubility at CPHI Barcelona
  • 13.3.11. Ingredion expands pharmaceutical excipients portfolio with strategic acquisitions in India
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Ashland Inc.
  • 13.4.2. Croda International PLC
  • 13.4.3. Clariant International Ltd.
  • 13.4.4. BASF SE

Companies Mentioned

• 1. ABITEC Corporation
• 2. Actylis
• 3. Asahi Kasei Corporation
• 4. Ashland Inc.
• 5. Avantor, Inc.
• 6. BASF SE
• 7. Clariant International Ltd.
• 8. Colorcon Ltd.
• 9. Croda International PLC
• 10. DFE Pharma GmbH & Co KG
• 11. Eastman Chemical Company
• 12. Evonik Industries AG
• 13. Fuji Chemical Industries Co., Ltd.
• 14. IMCD N.V.
• 15. Innophos Holdings, Inc.
• 16. International Flavors & Fragrances Inc.
• 17. JRS PHARMA GmbH + Co. KG
• 18. Kerry Group PLC
• 19. Meggle Group GmbH
• 20. Merck KGaA
• 21. Mitsubishi Chemical Group Corporation
• 22. NOF Corporation
• 23. Novo Nordisk A/S
• 24. Pfanstiehl, Inc.
• 25. Roquette Freres S.A.
• 26. Shin-Etsu Chemical Co., Ltd.
• 27. Sigachi Industries Limited
• 28. Spectrum Laboratory Products, Inc.
• 29. SPI Pharma, Inc. By Associated British Foods
• 30. The Archer-Daniels-Midland Company
• 31. The Dow Chemical Company
• 32. The Lubrizol Corporation
• 33. Wacker Chemie AG